
Aria CV is a medical device company developing a novel implantable system to treat pulmonary hypertension, a serious lung-related cardiovascular disease. Their device aims to restore healthy pulmonary artery function, reducing heart workload and improving blood flow and quality of life.

Investment Details
Funding Round
Series B
Milestones
Funded in 2020, 2022, and 2023

About the Founder
Dr. John Scandurra
Dr. Scandurra is a co-founder and Chief Scientific Officer at Aria CV, Inc., where he leads the development of Aria’s novel therapy for pulmonary hypertension and right heart failure. He is responsible for managing the company’s Scientific Advisory Board, fostering collaboration within the pulmonary hypertension physician community, and driving therapy development efforts. Before founding Aria, Dr. Scandurra was a Senior Fellow at the University of Minnesota’s Medical Devices Center, where he and his team invented Aria’s core technology. His multidisciplinary expertise spans medicine and engineering, bringing a unique perspective to medical innovation. Dr. Scandurra holds a Doctor of Veterinary Medicine (DVM) degree with post-doctoral clinical training in veterinary cardiology, as well as Bachelor’s and Master’s degrees in Mechanical Engineering.
Real Investors. Real Outcomes.
Start Your Investing Journey with Portfolia
Our live overview sessions are the best way to experience how Portfolia is transforming venture capital and why the experience is unmatched.
- MEET OUR PARTNERS
- LEARN HOW OUR FUNDS WORK
- SEE THE COMPANIES WE'RE BACKING.


